Intractable schizo-affective disorder successfully treated with electroconvulsive treatment over six years by Berg, John Erik
[page 102] [Mental Illness 2012; 4:e20]
Intractable schizo-affective disorder successfully treatedwith electroconvulsive treatment over six years
John E. Berg Oslo and Akershus University College,Faculty of health sciences, PB 4 St.Olavsplass, 0130 Oslo, Norway
Abstract
Some patients with severe mental disorders
are refractory to psychotherapeutic or psy-
chopharmacological interventions. We
describe a patient with severe symptoms from
the age of 16 to 44. Her illness is best
described as a schizo-affective disorder.
Several series of electroconvulsive therapy
(ECT) followed by maintenance once a week
for more than six years has kept her out of hos-
pital beds for three years. The patient demon-
strates the feasibility of  long term ECT and the
absence of disturbing cognitive reductions. 
Introduction
Patients not responding to psychotropic
medication are a challenge for psychiatrists
and facility staff. The burden on the families of
the patients is not only emotional, but also a
financial one.1,2 Some of these patients, with
affective symptoms as part of the primary diag-
nostic entity, may be helped by electroconvul-
sive treatment (ECT). This was already shown
in a paper penetrating the medical records of
the first series of patients treated by Meduna
in Budapest, albeit with camphor.3 Rabheru
and Persad reviewed the literature on continu-
ation and maintenance electroconvulsive ther-
apy in different patient groups in 1997.4 They
concluded that both continuation and mainte-
nance electroconvulsive therapy were effica-
cious, safe, well tolerated, and also cost-effec-
tive for patients with major psychiatric disor-
ders with depression. The procedure in itself is
deemed extremely safe according to Nuttal et
al. who studied 2279 patients given 17,394 ECT
treatments.5 No deaths were observed, and
only transient cardiac complications (arrhyth-
mias and one cardiac arrest) in 9 patients. The
adverse effects of ECT are related to the anaes-
thesia, which today is very short and practical-
ly without any danger of mortality. Headache
and nausea occur in some patients, and tran-
sient memory impairment is usual during the
time of a series of ECTs. 
An effect on cognition after maintenance
ECT has been studied. After four years and 180
maintenance treatments the initial slight
worsening of some cognitive functions in the
patient improved above pre ECT level.6 The
authors also reported on the longest series
given to one patient, 2400 treatments. A review
of the cognitive functioning in the elderly after
ECT concluded that global cognition remained
stable, whereas learning verbal information
and executive functioning was impaired.7 This
may contribute to the different findings in
studies. Cognition is a multifaceted mental
function that may be influenced by ECT, age,
nutritional status and other factors.8-10 A report
on a patient with severe catatonic depression
and autism showed cognitive and functional
stability during maintenance ECT for three
years.11
The indications for ECT around the world
differs, although the main indication is severe
depression, uni- or bipolar or as part of other
mental illnesses.12 Thus it would be of interest
to report on the treatment of a patient with
severe mental illness given ECT for more than
six years. 
Case Report
A 44-year old woman has been treated for
schizoaffective disorder with depressive,
manic and psychotic delusional episodes since
she was 18 years. She is unmarried, living
alone in a sheltered dwelling. Her parents are
in regular contact with her. We have no infor-
mation on untoward events during her child-
hood or adolescence. She has three siblings,
one with a bipolar disorder. Her illness started
at the age of 16, and from the age of 18 to 28
she had 10 resident stays at the psychiatric
acute department. For a long period she did
function well on clozapine, albeit with hospi-
talisations each year. The medication had to be
stopped because she developed agranulocyto-
sis. A computed tompgraphy (CT) scan of the
brain taken in 2004 showed expanded supra-
tentorial ventricles and slightly expanded tem-
poral horn. Later CT scans have not shown any
further deterioration. When she had to stop
taking clozapine she was started on ziprasi-
done, but the severe melancholiform depres-
sion with psychotic delusional thoughts per-
sisted. After a resident stay of more than a year
in the acute psychiatry department she sud-
denly developed a malignant neuroleptic syn-
drome. She was at the time on ziprasidone and
lithium. In the ensuing time she had periods
with mania with psychotic symptoms and more
catatonic episodes of depression interchange-
ably. As a last resort electroconvulsive treat-
ment was contemplated and started. She
improved after the first series, but several
series of ECT had to be given over a year to
maintain partial remission. From February
2005 she started receiving maintenance ECT.
This treatment is still continued. Initially she
got one session each week, from treatment
number 80-82 an interval of 14 days was tried.
Her functioning deteriorated dramatically, and
she was restarted on ECT once a week. From
treatment number 292 she has successfully
increased the distance to every tenth day. This
has given her somewhat greater flexibility in
life without worsening of symptoms. There are
at present no signs of reduction in cognitive
functions that could not be related to her hav-
ing been seriously ill for 28 years and/or hav-
ing received neuroleptics during the same
period. She is still taking neuroleptics that she
tolerates. Attempts at reducing the level of the
current medication have only partly been suc-
cessful. Serum level of quetiapine was 562
(reference range 50-700), but the level of the
metabolite of quetiapine was 3042 (i.e. more
than 5 times the level of quetiapine) on a test
half a year ago. The dose of quetiapine was
thus reduced from 1800 mg to 1600 mg a day.
The current doses (as of 2. January 2012) of all
medications are quetiapine 400 mg + 400 mg
+ 200 mg + 600 mg/day and chlorprotixen  25
mg ¥ 2, lorazepam 0.5 mg + 1 mg/day. In the
evening she gets 7.5 mg zopiclone and 20 mg
alimemazine. She started 2012 with her 348th
session of ECT. No medications are taken on
the morning of an ECT session.
Her psychopathological development may be
described as follows: the depressive and delu-
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sional symptoms were reduced after the first
series of ECTs she received. The improvement
did not last long, so she was entered on a sec-
ond series of ECTs. When 45 single treatments
had been given to her a decision was made to
continue with maintenance treatments with
sessions a week apart, Table 1. After more than
a year with stability in the depressive and psy-
chotic symptoms, and with little complicating
unrest and stress at sudden changes in plans,
treatment was continued at weekly intervals.
During the last half-year we have succeeded in
increasing the intervals from 7 to 10 days. She
is now in a stable state giving her the opportu-
nity to visit parents living abroad during a
whole week. Electroconvulsive therapy-procedure
ECT is performed in dedicated rooms in the
acute psychiatric department with an anaes-
thesiologist coming to the hospital. The treat-
ment is given with a Thymatron IVTM device.
Two EEG leads and pulse oxymeter readings
are registered together with the calculated out-
put from the Thymatron device. A protocol is
followed that gave rise to the information con-
tained in Table 1. A nurse surveys the patient
after the treatment. Most of her treatments
have been as a non-resident patient coming to
the hospital only for the sessions. She has not
had a resident stay for the last three years. The
first 250 treatments have been given with right
unilateral stimulating electrode placement,
Table 1. Thereafter a change to bifrontal stim-
ulation was made. This change was done part-
ly in an effort to improve efficacy and partly
because the patient was afraid of the stimula-
tion electrode gel would destroy her hair.13Anesthesia
250-350 mg thiopental and 50-60mg suc-
cinylcholine has been used over the years, and
no change of anaesthetics were needed when
we changed from right unilateral to bifrontal
stimulation at treatment session 250.
Venepuncture on both forearms has been pos-
sible during all the treatments. The patient has
not missed any scheduled session. 
Discussion
The present case demonstrates the success-
ful continuation of electroconvulsive treatment
over more than six years in a young woman
with a serious schizoaffective disorder. Her
definite improvement would be an argument
in the vivid on-going discussion by lay people
and psychologist/psychiatrists on cognitive
deficits after ECT.14-18 It is still disputed in the
literature, less among clinicians, whether ECT
as a maintenance option is effective. The NICE
guidelines (National Institute of Clinical
Excellence, technology appraisal 59) from 2003
are negative, but their conclusion is based on
mostly retrospective reports, and not the fol-
lowing study. In a prospective, controlled study
Swoboda et al. studied a group of patients
(N=42) with affective or schizoaffective disor-
der.19 They got either maintenance ECT +
pharmacotherapy or pharmacotherapy alone.
At 12 months the former group had a rehospi-
talisation rate of 33% and the latter 67%. Time
to relapse was also longer in the ECT group.
The results were somewhat poorer for the
schizoaffective cases. Frequent maintenance
ECT, as in our patient, may keep the incum-
bent out of hospital. The NICE guidelines con-
clusion may thus be irrelevant in these special
patients as mentioned in the most recent text-
book on ECT.20
Conclusions
The outcome years after a series of ECT may
in many cases not be very different from other
short-term treatment options as pharma-
Article
Table 1. Electroconvulsive treatment registration data for the patient.
Treatment Electrode Stimulus level EEG monitored Post ictal suppression Days between 
session placement (mColoumb) 100% = duration (sec) index % (PSI) treatments
number 504 mCoulomb
1-15 RUL 40% 27-56 41-93 2-10
16-30 RUL 40-70% 24-54 41-91 2-7
31-45 RUL 70-60-65-70 20-30 42-92 2-9
46-59 RUL 75-80-85 18-43 60-100 3-9
60-74 RUL 85-90 19-34 66-95 4-9
75-89 RUL 90-100-55* 17-40 77-97 7-14°
90-103 RUL 55-75 21-66 46-99 7-9
104-118 RUL 75-100 18.59 15-95 5-9
119-133 RUL 100 15-63 90-97 7-9
134-150 RUL 100 13-31 10-94 5-9
152-164# RUL 100 9-50 66-86 3-9
165-179 RUL 100 14-35 30-93 7-11
180-189 RUL 100 15-37 46-96 4-10
190-203 RUL 100 10-24 37-91 7-9
204-218 RUL 100 17-31 18-91 7-9
219-233 RUL 100 17-41 10-92 5-7
234-249 RUL 100 17-35 35-92 7-8
250-262 Bifrontal 40-50-60 19-49 46-94 7-8
263-276 Bifrontal 60 23-55 10-96 7-8
277-291 Bifrontal 60 21-55 74-96 7-8
292-306 Bifrontal 60 23-41 10-94 7-10
307-321 Bifrontal 60 23-56 10-98 9-11
* Reduction of stimulation level at change of treating doctor. No change in other parameters. ° Three treatments with an interval of 14 days. # No. 151 either not registered or missed in the sequence of treatments.
EEG, electroencephalogram; RUL, right unilateral electrode placement; Bifrontal, bifrontal electrode placement.
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cotherapy and/or psychotherapy for depres-
sions.21 Our patients are influenced by social,
economic and emotional factors after success-
ful ECT. These factors would mostly not be
related to the ECT as such. Helping patients
develop skills to cope with life are necessary,
but a task for other health professionals than
those giving the patient ECT. In a small follow
up study after ECT some patients committed
suicide long time after the end of the series.22
The patients had serious problems with coping
in life as assessed by the Sense of Coherence
test of Antonovsky.23 Long-term maintenance
treatment may thus contribute to a lower mor-
tality rate in severely depressed patients. 
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